TY - JOUR
T1 - Health-state utilities in long-term advanced melanoma survivors comparable with the general population
AU - Egeler, M. D.
AU - van de Poll-Franse, L. V.
AU - Tissier, R.
AU - Rogiers, A.
AU - Boers-Sonderen, M. J.
AU - van den Eertwegh, A. J.
AU - Hospers, G. A.
AU - de Groot, J. W. B.
AU - Aarts, M. J. B.
AU - Kapiteijn, E.
AU - Piersma, D.
AU - Vreugdenhil, G.
AU - van der Veldt, A. A.
AU - Suijkerbuijk, K. P. M.
AU - Neyns, B.
AU - Janssen, K. J.
AU - Blank, C. U.
AU - Retèl, V. P.
AU - Boekhout, A. H.
N1 - Funding Information: This work was supported by Bristol-Myers Squibb under Protocol number CA209483. Bristol-Myers Squibb, CA209483, Annelies H Boekhout Publisher Copyright: © 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
PY - 2023/9
Y1 - 2023/9
N2 - Background: Checkpoint inhibitors have been shown to substantially improve the survival of patients with advanced melanoma. With this growing group of survivors treated with immunotherapies, assessing their health-state utilities is essential and can be used for the calculation of quality-adjusted life years and for cost-effectiveness analyses. Therefore, we evaluated the health-state utilities in long-term advanced melanoma survivors. Methods: Health-state utilities were evaluated in a cohort of advanced melanoma survivors 24–36 months (N = 37) and 36-plus months (N = 47) post-ipilimumab monotherapy. In addition, the health-state utilities of the 24–36 months survivor group were assessed longitudinally, and utilities of the combined survival groups (N = 84) were compared with a matched control population (N = 168). The EQ-5D was used to generate health-state utility values, and quality-of-life questionnaires were used to establish correlations and influencing factors of utility scores. Results: Health-state utility scores were similar between the 24–36 months’- and the 36-plus months’ survival group (0.81 vs 0.86; p =.22). In survivors, lower utility scores were associated with symptoms of depression (β = − .82, p =.022) and fatigue burden (β = − .29, p =.007). Utility scores did not significantly change after 24–36 months of survival, and the utilities of survivors were comparable to the matched control population (0.84 vs 0.87; p =.07). Discussion: Our results show that long-term advanced melanoma survivors treated with ipilimumab monotherapy experience relatively stable and high health-state utility scores.
AB - Background: Checkpoint inhibitors have been shown to substantially improve the survival of patients with advanced melanoma. With this growing group of survivors treated with immunotherapies, assessing their health-state utilities is essential and can be used for the calculation of quality-adjusted life years and for cost-effectiveness analyses. Therefore, we evaluated the health-state utilities in long-term advanced melanoma survivors. Methods: Health-state utilities were evaluated in a cohort of advanced melanoma survivors 24–36 months (N = 37) and 36-plus months (N = 47) post-ipilimumab monotherapy. In addition, the health-state utilities of the 24–36 months survivor group were assessed longitudinally, and utilities of the combined survival groups (N = 84) were compared with a matched control population (N = 168). The EQ-5D was used to generate health-state utility values, and quality-of-life questionnaires were used to establish correlations and influencing factors of utility scores. Results: Health-state utility scores were similar between the 24–36 months’- and the 36-plus months’ survival group (0.81 vs 0.86; p =.22). In survivors, lower utility scores were associated with symptoms of depression (β = − .82, p =.022) and fatigue burden (β = − .29, p =.007). Utility scores did not significantly change after 24–36 months of survival, and the utilities of survivors were comparable to the matched control population (0.84 vs 0.87; p =.07). Discussion: Our results show that long-term advanced melanoma survivors treated with ipilimumab monotherapy experience relatively stable and high health-state utility scores.
KW - Advanced melanoma survivors
KW - EQ-5D
KW - Health-state utilities
KW - Quality-of-life
UR - http://www.scopus.com/inward/record.url?scp=85153335942&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s11136-023-03427-9
DO - https://doi.org/10.1007/s11136-023-03427-9
M3 - Article
C2 - 37079262
SN - 0962-9343
VL - 32
SP - 2517
EP - 2525
JO - Quality of life research
JF - Quality of life research
IS - 9
ER -